Egalet Corp (EGLT.OQ)
11 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|50||2015||Independent Chairman of the Board|
|52||2012||President, Chief Executive Officer, Director|
|55||2015||Chief Financial Officer, Executive Vice President, Secretary|
|45||2015||Chief Operating Officer, Executive Vice President|
|2015||Senior Vice President, General Counsel|
- BRIEF-Egalet Says Notified Verbally By CVS Caremark That Sprix Will No Longer Be On Formulary For A Portion Of Commercial Covered Lives Beginning 2018
- BRIEF-Egalet Corp's Phase 3 Study Of Egalet-002 In Patients With Moderate-To-Severe Chronic Low Back Pain Meets Primary Endpoint
- BRIEF-Egalet Corp Says Apotex Has Lost Right To Launch An Authorized Generic Version Of Sprix Nasal Spray
- BRIEF-EGALET ANNOUNCES LATE-STAGE STUDY DATA ON EGALET-002
- BRIEF-Egalet announces ARYMO ER added to large payer Medicare Part D Formulary